<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00529152</url>
  </required_header>
  <id_info>
    <org_study_id>LA30-0307</org_study_id>
    <nct_id>NCT00529152</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients</brief_title>
  <official_title>A 24-Week, Open Label, Uncontrolled Study of the Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients With Transfusion-Dependent Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ApoPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  The primary objective is to assess the safety of Ferriprox oral solution for the
           treatment of iron overload in pediatric patients with transfusion-dependent anemia.

        -  The secondary objective is to assess the efficacy of Ferriprox oral solution in reducing
           iron overload in pediatric patients with transfusion-dependent anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-centre, open label, single treatment, uncontrolled study. A total of 100
      iron-overloaded pediatric patients with transfusion-dependent anemia will be enrolled in the
      study.Eligible patients will receive Ferriprox (deferiprone) oral solution, 100 mg/mL, at a
      total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided in three (3)
      doses, for 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>24 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Ferritin Concentration From Baseline.</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ferriprox Oral Solution single treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone</intervention_name>
    <description>Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Ferriprox Oral Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are ≤ 10 years of age.

          -  Patients who have a confirmed diagnosis of transfusion-dependent anemia, other than
             Blackfan-Diamond anemia, and have chronic iron overload requiring chelation therapy.

          -  Patients who are in a chronic transfusion program, and who have received at least
             eight (8) red blood cell transfusions per year for a minimum of one year.

          -  Patients who are iron overloaded as assessed by serum ferritin concentration greater
             than 1000 µg/L.

        Exclusion Criteria:

          -  Patients who have a diagnosis of Blackfan-Diamond anemia.

          -  Patients who have experienced neutropenia/agranulocytosis (absolute neutrophil count
             (ANC) &lt; 1.5 x 109/L) or thrombocytopenia (platelet count &lt; 50.0 x 109/L).

          -  Patients who have had previous treatment with Ferriprox and presented serious adverse
             reaction or intolerance requiring withdrawal of Ferriprox.

          -  Patients with evidence of abnormal liver function (ALT level &gt; 3 times the upper limit
             of normal; entry may be delayed until values return to normal).

          -  Patients with evidence of renal failure, characterized by serum creatinine level &gt; 2
             times the upper limit of normal; entry may be delayed until values return to normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Mohsen S El Alfy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children Hospital, Ain Shams University, Cairo, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abo El Reish Hospital, Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Hospital, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cipto Mangunkusumo National Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>10010</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Center</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Indonesia</country>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2007</study_first_posted>
  <results_first_submitted>June 26, 2009</results_first_submitted>
  <results_first_submitted_qc>August 11, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2009</results_first_posted>
  <last_update_submitted>August 25, 2009</last_update_submitted>
  <last_update_submitted_qc>August 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dian Shaw</name_title>
    <organization>ApoPharma Inc.</organization>
  </responsible_party>
  <keyword>Iron Overload</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iron Overload</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ferriprox Oral Solution</title>
          <description>All subjects were administered Ferriprox Oral Solution three times daily for a total daily dose of either 50, 75 or 100 mg/kg/day. Subjects were initiated at a dose of 50 mg/kg/day, but this dose could be increased after two weeks of therapy depending on the subjects' individual needs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ferriprox Oral Solution</title>
          <description>All subjects were administered Ferriprox Oral Solution three times daily for a total daily dose of either 50, 75 or 100 mg/kg/day. Subjects were initiated at a dose of 50 mg/kg/day, but this dose could be increased after two weeks of therapy depending on the subjects' individual needs.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.1" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indonesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>serum ferritin</title>
          <description>serum ferritin measures the amount of iron in the blood</description>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2531.7" spread="1463.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Occurrence of Adverse Events</title>
        <description>Number of Adverse Events over 24 weeks</description>
        <time_frame>24 Weeks</time_frame>
        <population>All subjects enrolled (100), had at least one dose of Ferriprox oral solution, all were included in safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Ferriprox Oral Solution</title>
            <description>All subjects were administered Ferriprox Oral Solution three times daily for a total daily dose of either 50, 75 or 100 mg/kg/day. Subjects were initiated at a dose of 50 mg/kg/day, but this dose could be increased after two weeks of therapy depending on the subjects' individual needs.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Adverse Events</title>
          <description>Number of Adverse Events over 24 weeks</description>
          <population>All subjects enrolled (100), had at least one dose of Ferriprox oral solution, all were included in safety analysis</population>
          <units>Adverse Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Ferritin Concentration From Baseline.</title>
        <description>The change in serum ferritin concentration from baseline to week 24 was measured and analyzed for all participants in the study</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>99 subjects had at least one post baseline measurement of serum ferritin concentration and were eligible for the efficacy analyses in the Intent to Treat population (all subjects). The Last Measurement Carried Forward methodology was used to populate any missing serum ferritin value.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferriprox Oral Solution</title>
            <description>All subjects were administered Ferriprox Oral Solution three times daily for a total daily dose of either 50, 75 or 100 mg/kg/day. Subjects were initiated at a dose of 50 mg/kg/day, but this dose could be increased after two weeks of therapy depending on the subjects' individual needs.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Ferritin Concentration From Baseline.</title>
          <description>The change in serum ferritin concentration from baseline to week 24 was measured and analyzed for all participants in the study</description>
          <population>99 subjects had at least one post baseline measurement of serum ferritin concentration and were eligible for the efficacy analyses in the Intent to Treat population (all subjects). The Last Measurement Carried Forward methodology was used to populate any missing serum ferritin value.</population>
          <units>ug/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-355.5" spread="978.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in Serum Ferritin from baseline to week 24 was compared using regression analysis; null hypothesis was defined as no change in serum ferritin from baseline to week 24</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Regression, Linear</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right to review manuscript at least 60 days prior to submission and posters/abstracts at least 30 days. If review indicates potentially patentable or confidential information would be disclosed, submission may be delayed an extra 30 days to allow filing the necessary patent applications and to co-operate with the sponsor to protect confidential information. Investigator will delay single center publications until after disclosure of pooled data (all sites) by Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dian Shaw, Manager Clinical Research</name_or_title>
      <organization>ApoPharma</organization>
      <phone>416-401-7283</phone>
      <email>dshaw@apotex.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

